The stock of Celldex Therapeutics Inc (CLDX) has seen a 3.03% increase in the past week, with a 10.72% gain in the past month, and a 31.22% flourish in the past quarter. The volatility ratio for the week is 7.12%, and the volatility levels for the past 30 days are at 6.75% for CLDX. The simple moving average for the past 20 days is 6.67% for CLDX’s stock, with a -7.86% simple moving average for the past 200 days.
Is It Worth Investing in Celldex Therapeutics Inc (NASDAQ: CLDX) Right Now?
CLDX has 36-month beta value of 1.22. Analysts have mixed views on the stock, with 11 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CLDX is 64.51M, and currently, short sellers hold a 12.14% ratio of that float. The average trading volume of CLDX on July 03, 2025 was 996.41K shares.
CLDX) stock’s latest price update
The stock price of Celldex Therapeutics Inc (NASDAQ: CLDX) has surged by 4.24% when compared to previous closing price of $21.21, but the company has seen a 3.03% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-14 that HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.
Analysts’ Opinion of CLDX
Many brokerage firms have already submitted their reports for CLDX stocks, with Canaccord Genuity repeating the rating for CLDX by listing it as a “Buy.” The predicted price for CLDX in the upcoming period, according to Canaccord Genuity is $64 based on the research report published on April 28, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $46. The rating they have provided for CLDX stocks is “Overweight” according to the report published on March 20th, 2025.
UBS gave a rating of “Buy” to CLDX, setting the target price at $44 in the report published on February 13th of the current year.
CLDX Trading at 9.27% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.96% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Marucci Anthony S, who purchase 11,500 shares at the price of $26.82 back on Nov 11 ’24. After this action, Marucci Anthony S now owns 40,284 shares of Celldex Therapeutics Inc, valued at $308,430 using the latest closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -28.74 for the present operating margin
- 0.79 for the gross margin
The net margin for Celldex Therapeutics Inc stands at -23.66. The total capital return value is set at -0.31. Equity return is now at value -23.20, with -22.24 for asset returns.
Based on Celldex Therapeutics Inc (CLDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -50.03.
Currently, EBITDA for the company is -191.9 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 192.39. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.67.
Conclusion
To put it simply, Celldex Therapeutics Inc (CLDX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
